Funding - January 19, 2017
Five members granted funding by Innovation Norway
To stimulate collaboration between companies in the Oslo Cancer Cluster, the cluster have through Innovation Norway´s funding scheme “Innovasjonsrammen” granted five member companies project funding between NOK 500 000 – 100 000. PCI Biotech, Ultimovacs, Arctic Pharma, Oncoimmunity and MyHere are the lucky companies, and they will all use the funding to develop improved cancer treatments. “Oslo […]
Uncategorized - September 21, 2016
Obama receives a helping hand from Norway
US President Obama’s cancer project collaborates with the Oslo Cancer Cluster in order to find breakthroughs in cancer prevention and treatment. Last week, Oslo Cancer Cluster’s CEO Ketil Widerbrg together with Jason Paragas from the Lawrence Livermore Research Laborator were interviewed by Norwegian Television about the role of cooperation and super-computers in finding better cancer […]
In a new job - June 27, 2016
OCC makes new recruitment
The OCC Incubator has recruited Nadine Lohs to be responsible for the operation of the Incubator from 1st August. Nadine Lohs is from Austria and has recently completed her Master of International Health and Social Management at the Management Center Innsbruck. She has had an internship at Oslo Cancer Cluster Incubator this Spring.
Funding - March 22, 2016
OCC & NCE Smart Energy Markets partner in EU project of 45 MNOK
Oslo Cancer Cluster and NCE Smart Energy Markets together with four European clusters in medicine and IT managed to land a prestigious Horizon 2020 EU project. The EU project will use innovative IT solutions to develop personalized cancer treatment. Allocated funds is 45 million, of which 34 million is earmarked for small and medium enterprises […]
Uncategorized - February 3, 2016
World Cancer Day
On Thursday February 4th it is World Cancer Day. Oslo Cancer Cluster is for example paying a tribute by organizing a breakfast meeting together with the Cancer Registry of Norway and the Cancer Society of Norway. The theme for the breakfast meeting, starting 8:30 am at Kreftforeningen, Kongens gate 6, Oslo, is colorectal cancer, one of […]
Financing - February 2, 2016
Vaccibody granted NOK 20 million
Vaccibody has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program to develop therapeutic cancer vaccines based on each patient’s specific neoantigens. Neoantigens are tumour- specific mutations in cancer cells. While most commonly shared tumour antigens used in cancer vaccines to date […]
